How Sarclisa Performs in Key Trials
Sarclisa (isatuximab-irfc) is a CD38-targeting monoclonal antibody approved for relapsed/refractory multiple myeloma (RRMM), often combined with pomalidomide and dexamethasone (Isa-Pd). In the ICARIA-MM phase 3 trial, Isa-Pd extended median progression-free survival (PFS) to 11.9 months versus 6.5 months for pomalidomide-dexamethasone alone (hazard ratio [HR] 0.60; 95% CI 0.47-0.77; p<0.0001). Overall survival (OS) showed a trend favoring Isa-Pd (HR 0.78), but it did not reach statistical significance.1
Sarclisa vs. Darzalex (Darzalex, daratumumab)
Darzalex, the first CD38 antibody, sets the benchmark. Direct head-to-head trials are lacking, but cross-trial comparisons highlight differences:
| Endpoint | Sarclisa (Isa-Pd, ICARIA-MM) | Darzalex (D-Pd, APOLLO) | Darzalex (D-Vd, CASTOR) |
|----------|------------------------------|--------------------------|--------------------------|
| Median PFS | 11.9 months | 12.7 months (HR 0.63 vs Pd) | 16.6 months (HR 0.47 vs Vd) |
| ORR | 60% | 69.9% | 83% |
| Patient population | ≥3 prior lines | ≥2 prior lines | ≥1 prior line |
| MRD negativity | 2.9% | 4.6% | 6.6% |
Sarclisa shows comparable PFS benefit to D-Pd in more heavily pretreated patients but lags in overall response rate (ORR) and minimal residual disease (MRD) negativity. Darzalex excels in earlier lines and with bortezomib (D-Vd).14 Real-world data suggest similar OS trends, with Darzalex linked to slightly better depth of response due to broader CD38 binding affinity.5
Why Sarclisa's Mechanism Differs
Both bind CD38, but Sarclisa induces higher antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis via NK cells, while Darzalex emphasizes complement-dependent cytotoxicity (CDC). Sarclisa avoids FDA warnings for reactivation of hepatitis B virus, unlike early Darzalex formulations. These traits make Sarclisa viable post-Darzalex exposure, where 29% of ICARIA patients had prior CD38 therapy.2
Overall Survival and Long-Term Outcomes
No CD38 antibody significantly improves OS as monotherapy. In RRMM:
- Sarclisa: 24.6-month median OS with Isa-Pd vs 22.2 months (ICARIA).
- Darzalex: 29.6 months with D-Pd vs 25.3 months (APOLLO); 49.5 months with D-Vd (CASTOR update).
Frontline data (newly diagnosed MM) favor quadruplets like Darzalex-VRd (PFS not reached at 48 months, PERSEUS) over Sarclisa combinations.37 Sarclisa's niche is later lines, with less neurotoxicity than Darzalex in some analyses.
Patient Tolerability and Real-World Use
Infusion reactions occur in 51% of Sarclisa patients (mostly grade 1/2) vs 41% for Darzalex. Cytopenias are common across both (neutropenia ~50%), but Sarclisa has lower rates of grade 3+ infections (28% vs 35% for D-Pd). In practice, Sarclisa is sequenced after Darzalex failure, with response rates of 30-40% in prior-CD38 exposed patients.5
Emerging Competitors and Future Outlook
Other CD38 antibodies like MOR202 (felzartamab) are in trials but not approved. Bispecifics (e.g., teclistamab) outperform monoclonals in heavily pretreated RRMM (PFS 11.2 months, MajesTEC-1), shifting the landscape. Patents for Sarclisa expire around 2033; check DrugPatentWatch.com for updates.9
Sources